Adherium Announces Research Study with Connecticut Children’s Medical Center to Explore Best Practices for Access to Better Asthma Care Nationally

Adherium Announces Research Study with Connecticut Children’s Medical Center to Explore Best Practices for Access to Better Asthma Care Nationally

10 Jul 2018

San Mateo, CA – July 10, 2018: Adherium (ASX: ADR), a leading digital health company that improves medication adherence and patient outcomes, today announced a research study with Connecticut Children’s Medical Center to try to help patients with asthma manage their condition with Adherium’s technology, the Hailie solution.

Connecticut Children’s Medical Center’s close work with the U.S. Medicaid program – ensuring families in need have proper access to healthcare – will provide new insights on how the Hailie™ solution can support underserved families and their communities.

Connecticut Children’s Medical Center is dedicated to improving the physical and emotional health of children through family-centered care, research, education and advocacy. The research study will be led by Dr. Tregony Simoneau, and serves more than 100 patients with existing asthma. 

“This strategic research program with Connecticut Children’s Medical Center allows for further acceleration of our work in the U.S., realizing additional improvements in care and patient engagement here and globally,” said Arik Anderson, CEO of Adherium. “Clinical results show the benefits of adherence to disease management, and reduced cost to the healthcare system. The implications for patient populations that can find themselves stretched beyond their means are obvious. Hailie is a solution uniquely focused on strengthening and multiplying the benefits of physician engagement with families. We are eager to work with Connecticut Children’s Medical Center to further explore best practices, together with their families.”

“Connecticut Children’s Medical Center is really focused on making disease management easy and smart for all families,” said Tregony Simoneau, MD. “We look for innovative ways of providing care to patients and families. We ask questions, invest in research, find answers and share new knowledge with the world. We partner with families and embrace their involvement in all aspects of service and care, and Hailie offers us a new way of doing that. By leveraging smarter technology, we help underserved populations, which in turn could produce tremendous cost savings for payers.”

The Hailie sensor is a device that wraps around a patient’s inhaler to monitor and promote asthma adherence as part of a self-management plan.  It records the date and precise time the inhaler is used and automatically transmits this to an app on the patient’s phone or tablet. Hailie’s sensor design helps patients easily access the audio visual-reminders, battery monitoring, and Bluetooth® wireless technology.

With the Hailie solution, which captures the history of patient medication usage patterns, physicians can review and make evidence-based decisions. The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for Adherium’s Hailie (previously known as Smartinhaler™) sensors for use with a number of inhaler medicatons.

“Connecticut Children’s Medical Center and Adherium share a vision for evidence-based support for patients and their families in implementing their physicians’ guidance into their daily lives,” said Tim Houchin, Adherium’s VP of Sales. “Hailie brings together the most clinically proven precision monitoring with low-friction coaching. Our technology eliminates obstacles standing between physicians and patients, leveraging more than 15 years of research into respiratory medication usage.” 

According to the U.S. Centers for Disease Control and Prevention, in 2008, an estimated 88,350 children in Connecticut had asthma. In a survey conducted that same year, 30 percent of respondents said they have been given an asthma action plan, and 8 percent have taken a course on how to manage asthma. The Connecticut State Department of Public Health reports Asthma prevalence in the state’s adults and children has been higher than national prevalence rates since the year 2000. 

Despite advances in therapies and understanding of respiratory disease, asthma remains the third-leading cause of hospitalization for children in the U.S. under 15 years old, and the leading cause of missed school days, resulting in more than $80 billion a year in costs.

About Adherium

Adherium is a provider of digital health solutions and a global leader in connected respiratory medical devices, with over 100,000 distributed globally. The Company develops, manufactures and supplies patients, pharmaceutical companies, healthcare providers and contract research organizations with the broadest range of connected medical devices for respiratory medications. The devices and accompanying technology address sub-optimal medication use and strive to improve health outcomes in chronic disease. Adherium is headquartered in the USA, and operates globally from bases in the U.S., Europe and Australasia. Learn more at adherium.com.

 

Inquiries

Vik Panda, Adherium

Email: vikp@adherium.com

 

Media

Chris Gale, Greentarget

Phone: 646.695.2883

Email: cgale@greentarget.com

 

Investors

Leigh Salvo, Gilmartin Group

Phone: 415.937.5404

Email: leigh@gilmartinir.com